Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial.
Alavi Darazam I, Hatami F, Mahdi Rabiei M, Amin Pourhoseingholi M, Shabani M, Shokouhi S, Mardani M, Moradi O, Javandoust Gharehbagh F, Mirtalaee N, Negahban H, Amirdosara M, Zangi M, Hajiesmaeili M, Kazempour M, Shafigh N. Alavi Darazam I, et al. Int Immunopharmacol. 2021 Oct;99:107916. doi: 10.1016/j.intimp.2021.107916. Epub 2021 Jun 29. Int Immunopharmacol. 2021. PMID: 34224994 Free PMC article. Clinical Trial.
Statins and postoperative infections: a randomized clinical trial.
Shokouhi S, Alavi Darazam I, Sharifi G, Gachkar L, Amirsardari A, Samadian M. Shokouhi S, et al. Among authors: alavi darazam i. Jundishapur J Microbiol. 2014 Apr;7(4):e9456. doi: 10.5812/jjm.9456. Epub 2014 Apr 1. Jundishapur J Microbiol. 2014. PMID: 25147705 Free PMC article.
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I, Hatami F, Rabiei MM, Pourhoseingholi MA, Moradi O, Shokouhi S, Hajesmaeili MR, Shabani M, Irvani SSN. Alavi Darazam I, et al. Trials. 2020 Oct 26;21(1):880. doi: 10.1186/s13063-020-04812-2. Trials. 2020. PMID: 33106183 Free PMC article. Clinical Trial.
Early recovery of botulism: one decade of experience.
Hatami F, Shokouhi S, Mardani M, Shabani M, Gachkar L, Alavi Darazam I. Hatami F, et al. Among authors: alavi darazam i. Clin Toxicol (Phila). 2021 Jul;59(7):628-632. doi: 10.1080/15563650.2020.1844225. Epub 2020 Nov 6. Clin Toxicol (Phila). 2021. PMID: 33156710
Antipseudomonal β-Lactams Resistance in Iran.
Rabiei MM, Asadi K, Shokouhi S, Nasiri MJ, Alavi Darazam I. Rabiei MM, et al. Among authors: alavi darazam i. Int J Microbiol. 2020 Dec 16;2020:8818315. doi: 10.1155/2020/8818315. eCollection 2020. Int J Microbiol. 2020. PMID: 33488724 Free PMC article. Review.
Post-mortem Histopathologic Findings of Vital Organs in Critically Ill Patients with COVID-19.
Bidari Zerehpoosh F, Sabeti S, Bahrami-Motlagh H, Mokhtari M, Naghibi Irvani SS, Torabinavid P, Esmaeili Tarki F, Amirdosara M, Rezaei O, Mostafazadeh B, Hajiesmaeili M, Rabiei MM, Alavi Darazam I. Bidari Zerehpoosh F, et al. Among authors: alavi darazam i. Arch Iran Med. 2021 Feb 1;24(2):144-151. doi: 10.34172/aim.2021.23. Arch Iran Med. 2021. PMID: 33636984 Free article.
46 results